Aurobindo Pharma (AUROPHARMA) — Announcement

📢 Key Event
US FDA completes inspection at Lannett subsidiary with four procedural observations

💡 Investor Takeaway
The FDA inspection outcome poses no immediate financial or operational risk but highlights the company's quality compliance focus.

Aurobindo Pharma announced that its US FDA inspection of Lannett Company LLC, a wholly owned subsidiary, concluded on August 21, 2026, with four procedural observations. The company confirmed it will address these within the regulatory timeline and will keep exchanges updated on any further developments. This inspection underscores ongoing compliance efforts at its US manufacturing unit.

📄 View Original Announcement (PDF)

📊 Stock Analysis — AUROPHARMA ✨ Ask AI About This

About Aurobindo Pharma Limited (AUROPHARMA)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹97,238.86 Cr P/E: 26.4 ROE: 9.8% ROCE: 12.8% Div Yield: 0.24%

View full AUROPHARMA stock details →

📡 Get AI alerts when AUROPHARMA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track AUROPHARMA — Free

💡 Ask AI about this filing

"How will Aurobindo address the four FDA observations?" "What is the timeline for FDA response resolution?" "How does this inspection affect US revenue expectations?"

Ask AI Free →

📊 More AUROPHARMA filings

See all AUROPHARMA filings →

🔥 Also filed on 24 August 2026

BALAJITELE Balaji Telefilms Limited Corporate Action PATINTLOG Patel Integrated Logistics Limited Corporate Action SKIL SKIL Infrastructure Limited Announcement RHL Robust Hotels Limited Annual Report AAVAS Aavas Financiers Limited Annual Report CTE Cambridge Technology Enterprises Limited Announcement

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when AUROPHARMA files new disclosures

Track AUROPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track AUROPHARMA — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd